BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35512686)

  • 21. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
    Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
    World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of differential cyclin D1 expression and localisation in prostate cancer.
    Comstock CE; Revelo MP; Buncher CR; Knudsen KE
    Br J Cancer; 2007 Mar; 96(6):970-9. PubMed ID: 17375037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.
    Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D
    World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis.
    Wang Q; Li M; Zhang X; Huang H; Huang J; Ke J; Ding H; Xiao J; Shan X; Liu Q; Bao B; Yang L
    Exp Mol Pathol; 2016 Jun; 100(3):514-21. PubMed ID: 27155449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Washington SL; Cowan JE; Herlemann A; Zuniga KB; Masic S; Nguyen HG; Carroll PR
    Prostate; 2021 Feb; 81(2):102-108. PubMed ID: 33075151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
    Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
    BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.
    Raatikainen S; Aaltomaa S; Palvimo JJ; Kärjä V; Soini Y
    Scand J Urol; 2015 Feb; 49(1):51-7. PubMed ID: 24779451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
    Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
    Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.